

## Accepted Manuscript

Title: Cardiovascular risk analysis by means of pulse morphology and clustering methodologies

Author: Vânia G. Almeida J. Borba H. Catarina Pereira Tânia Pereira Carlos Correia Mariano Pêgo João Cardoso



PII: S0169-2607(14)00244-2  
DOI: <http://dx.doi.org/doi:10.1016/j.cmpb.2014.06.010>  
Reference: COMM 3816

To appear in: *Computer Methods and Programs in Biomedicine*

Received date: 16-9-2013  
Revised date: 12-6-2014  
Accepted date: 17-6-2014

Please cite this article as: Vânia G. Almeida, J. Borba, H. Catarina Pereira, Tânia Pereira, Carlos Correia, Mariano Pêgo, João Cardoso, Cardiovascular risk analysis by means of pulse morphology and clustering methodologies, *Computer Methods and Programs in Biomedicine* (2014), <http://dx.doi.org/10.1016/j.cmpb.2014.06.010>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Highlights

- We developed a clustering methodology to deal with Arterial Pressure Waveform (APW) parameters.
- A new non-invasive device is being evaluated.
- We collect a database of 116 subjects.
- This study compares different methods used in the APW analysis toward cardiovascular diseases.
- It is possible to assess potential cardiovascular risk in healthy subjects using cluster analysis.

Accepted Manuscript

## Cardiovascular risk analysis by means of pulse morphology and clustering methodologies

Vânia G. Almeida<sup>1</sup>, J. Borba<sup>1</sup>, H. Catarina Pereira<sup>1,2</sup>, Tânia Pereira<sup>1</sup>, Carlos Correia<sup>1</sup>,  
Mariano Pêgo<sup>3</sup> and João Cardoso<sup>1</sup>

<sup>1</sup> *Physics Department, Electronics and Instrumentation Group, University of Coimbra*

<sup>2</sup> *Intelligent Sensing Anywhere*

<sup>3</sup> *Cardiology Department, Hospital and University Coimbra Center*

---

### Abstract

The purpose of this study was the development of a clustering methodology to deal with Arterial Pressure Waveform (APW) parameters to be used in the cardiovascular risk assessment. One hundred sixteen subjects were monitored and divided in two groups. The first one (23 hypertensive subjects) was analysed using APW and biochemical parameters, while the remaining 93 healthy subjects were only evaluated through APW parameters. The Expectation Maximization (EM) and  $k$ -means algorithms were used in the cluster analysis, and the risk scores (the Framingham Risk Score (FRS), the Systematic COronary Risk Evaluation Project (SCORE), the Assessing cardiovascular risk using Scottish Intercollegiate Guidelines Network guidelines (ASSIGN) and the PROspective Cardiovascular Münster (PROCAM)), commonly used in clinical practice were selected to the cluster risk validation. The result from the clustering risk analysis showed a very significant correlation with ASSIGN ( $r = 0.582$ ,  $p < 0.01$ ) and a significant correlation with FRS ( $r = 0.458$ ,  $p < 0.05$ ). The results from the comparison of both groups also allowed to identify the cluster with higher cardiovascular risk in the healthy group. These results give new insights to explore this methodology in future scoring trials.

---

*Email address: vaniagalmeida@lei.fis.uc.pt (Vânia G. Almeida<sup>1</sup>)*

*Preprint submitted to Elsevier*

*June 12, 2014*

1  
2  
3  
4  
5  
6  
7  
8  
9 *Keywords:* Arterial Stiffness, Pulse Wave Analysis, Risk Scores, Clustering Analysis

---

10  
11  
12 **1. Introduction**

13  
14  
15 The atherosclerotic Cardiovascular Disease (CVD) is the most common cause of  
16 death worldwide, resulting from the combination of several risk factors [1]. The  
17 international guidelines [2, 3] consider that individuals with established CVD should  
18 be the first priority for preventive measures application. The concern in changing the  
19 current healthcare paradigm, from reactive towards preventive care, aims at identify  
20 individuals for risk in early stages of disease development, and then, direct more  
21 efforts and attention to the risk factors modification [4, 5]. Fortunately, this is an  
22 emergent tendency that can be addressed using the traditional risk scores, but also  
23 using innovative predictive algorithms.

24  
25  
26 During the last years many risk estimation systems have been developed in order  
27 to assist clinicians in the risk assessment, and in the individual chances prediction, for  
28 CVD development. The major challenges of these tools are the capabilities to: (1)  
29 identify high risk individuals, (2) weight the individual effects of all risk factors, (3)  
30 stratify or organize who needs lifestyle advice or medical therapy, and finally (4) avoid  
31 overmedicalization of individuals at low risk [6]. Taking this challenges into account  
32 several risk factors were identified, by their association with an increased risk for CVD  
33 development. CVD risk assessment tools differ from each other on the selected risk  
34 factors, the disease for what they were designed (Coronary Heart Disease (CHD),  
35 heart failure, *etc.*), the selected event type, the considered period of time (long or  
36 short term) and the cohort location. The most popular are: Framingham Risk Score  
37 (FRS), PROspective Cardiovascular Münster (PROCAM), ASsessing cardiovascular  
38 risk using Scottish Intercollegiate Guidelines Network (ASSIGN) and Systematic  
39 COronary Risk Evaluation project (SCORE).

40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

205 These tools are important to help physicians in their daily practice. However,

1  
2  
3  
4  
5  
6  
7  
8  
9  
26 its application in different populations remains a topic concerning attention. The  
10  
27 research needs to be directed at refining the accuracy of prediction models and, most  
11  
28 importantly, examining ways of turning them into effective clinical tools. Several risk  
12  
29 prediction models for cardiovascular disease are available today and their head to head  
13  
30 comparison and application in different populations would benefit from standardized  
14  
31 reporting and formal, consistent statistical comparisons. The work presented by [7]  
15  
32 reinforces this statement. The limitations of the comparison of different methods is  
16  
33 associated to missing information, which makes difficult to reach robust conclusions  
17  
34 about the best model or the ranking of models' performance. And, additionally most  
18  
35 studies did not statistically compare the models that were examined. The inclusion  
19  
36 of standardized reporting of discrimination, calibration, and reclassification metrics  
20  
37 with formal statistical comparisons would contribute to the successful application of  
21  
38 different risk scores in distinct populations.

31  
32 The trends for the risk overestimation in low-risk populations and underestimation  
33  
40 in high-risk groups have been successfully demonstrated by Cooney, *et al.* [6]. It  
34  
41 is known that an examination of 5 % SCORE can equate to a 10 – 25 % FRS risk,  
35  
42 depending on which of the several FRS functions is selected [3]. Haq, *et al.* [8]  
36  
43 studied several methods for risk estimation (FRS, PROCAM, Dundee, and British  
37  
44 regional heart-BRHS) and the results demonstrated a close agreement between all  
38  
45 these, regarding average risk and showed moderate agreement for estimation among  
39  
46 individuals. Finally, it was also concluded that FRS function is acceptably accurate in  
40  
47 northern European populations.

41  
48 The arterial stiffness measurement currently assumes an increasing role in clinical  
42  
49 assessment due to its predictive value in cardiovascular events in patients with various  
43  
50 risk levels, such as it was demonstrated by several studies [9, 10, 11, 12]. There are  
44  
51 several advantages of using non-invasive methods over invasive measurements, *e.g.*, the  
45  
52 potential use in follow-up strategies in populations without symptomatic CVD, such as

1  
2  
3  
4  
5  
6  
7  
8  
9 53 children or young adults. Furthermore, non-invasive tools can be essential to the CVD  
10 54 assessment in addition to the established risk factors in populations at high risk aiming  
11 55 the prevention of coronary vascular diseases. Inferences about CVD progressive  
12 56 development can be assessed by the analysis of the mechanical properties of arteries  
13 57 through a variety of indices based on the Pulse Wave Analysis (PWA) [13, 14]. The  
14 58 analysis is based on the identification of the key features in the arterial pressure wave  
15 59 profile, such as Systolic Wave Transit Time (SWTT), Reflected Wave Transit Time  
16 60 (RWTT) and dirotic notch (evaluated by Left Ventricular Ejection Time (LVET)), and  
17 61 can include time or amplitude considerations, as well as variability based parameters  
18 62 [15]. The wave reflections are often addressed, in terms of the Augmentation Index  
19 63 (AIx), which expresses the ratio of the “augmented pressure” assigned to the reflected  
20 64 wave towards each overall pulse.

21 65 Data mining techniques have attracted a great deal of attention due to their ability  
22 66 to extract implicit and potentially useful information from large volumes of data [16].  
23 67 Their feasible implementation in Computer-Aided Diagnosis (CAD) methodologies  
24 68 has given new insights in the development of innovative and effective decision support  
25 69 systems for CVD premature risk assessment [15, 17, 18, 19]. An interesting approach  
26 70 is the exploration of different classifiers, as it was proposed by Jovic *et al.* [20]. The  
27 71 electrocardiogram (ECG) classification problem was addressed using a combination of  
28 72 several features in the analysis of the Heart Rate Variability (HRV). Other approach  
29 73 presented by Tsipouras *et al.* [18] was based on the development of a fuzzy rule-  
30 74 based decision support system for CAD diagnosis. On the other hand, multi-classifiers  
31 75 should perform better in some situations, overcoming errors from single classifier  
32 76 analysis [21]. The incorporating of the prediction outcome of each one of the individual  
33 77 classifier was suggested, as a way to reduce the classification errors [22].

34 78 On other hand, clustering analysis is another important branch of unsupervised  
35 79 learning that allows the arrangement of objects into groups (*i.e.*, the clusters), wherein  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

80 the objects in the same cluster are more similar (in one or more characteristics), than  
81 those in different clusters [23]. There is a wide variety of clustering methodologies  
82 available in literature, essentially organized in three general classes [24]. The  
83 three types include parametric model-based, hierarchical and partitioning algorithms.  
84 Shah *et al.* [25] has proved the usefulness and feasibility of using clustering risk  
85 factors in the detection of CVD in youth, by the comparison with the Pathobiological  
86 Determinants of Atherosclerosis in Youth (PDAY) risk score. Other studies have also  
87 referred the role of clustering methodologies for CVD assessment, such as the work  
88 developed by Haseena *et al.* [26], where a fuzzy C-mean clustered probabilistic neural  
89 network for ECG beats discrimination was described. Clustering methodologies were  
90 also successful applied in other medical fields, such as in the identification of patterns  
91 in blood glucose measurements and regular insulin doses taken before meal time [27].

92 Our aim is the development of a clustering methodology to deal with Arterial  
93 Pressure Waveform (APW) based parameters to cardiovascular risk assessment. The  
94 evaluation was performed through the strength of the relationships with traditional risk  
95 scores. In the current paper, Section 2 details the subjects and methods used during data  
96 analysis, including a quick and up-to-date literature survey on attempts for risk scores  
97 and clustering methods used. The results are presented and discussed in Sections 3 and  
98 4, respectively. Finally, in Section 5 some guidelines for further research are presented  
99 along with the main conclusions of the current work.

## 100 **2. Methodology**

### 101 *2.1. Database*

102 The data used in this study were obtained from 116 subjects divided in two groups,  
103 as depicted in Figure 1(a). Data were collected with approval by the ethical committees  
104 of the Coimbra Hospital and University Centre (CHUC), Portugal, with informed  
105 consent. Hypertension was diagnosed when Systolic Blood Pressure (SBP)  $\geq 140$

1  
2  
3  
4  
5  
6  
7  
8  
9  
106 mmHg and/or Diastolic Blood Pressure (DBP)  $\geq$  90 mmHg, or if the patient was taking  
107 anti-hypertensive medication. Age, smoking habits, and familiar hypertensive history  
108 were recorded by structured questioning in accordance with the criteria used by each  
109 one of the scores. Current smoking was defined as having smoked the last cigarette less  
110 than 1 year before. Diabetes mellitus was considered for those subjects that presented a  
111 fasting blood sugar level  $>$ 126 mg/dl, or current prescription of an oral hypoglycemic  
112 drug or insulin.

113 Two groups of subjects were analysed: Group C and Group H. The group H  
114 inclusion criteria included diagnosed hypertension by a clinician and for Group C  
115 young subjects without any known cardiovascular complication.

116 • Group H consists of 23 hypertensive subjects, 10 men and 13 women. Lipidic  
117 values were measured: the serum total cholesterol (Total-CH), the high density  
118 lipoprotein cholesterol (CH-HDL) and the triglyceride (TGL) levels. All subjects  
119 were tested at the same time of day to avoid any diurnal variations. Additionally,  
120 the APW parameters were also computed: SWTT, RWTT, SWA, LVET and AIX.

121 • Group C consists of 93 young and healthy subjects between 18 – 30 years. The  
122 APW parameters were computed: SWTT, RWTT, SWA, LVET and AIX.

## 123 2.2. PWA Measurements

124 APWs were recorded at a sampling rate of 1 kHz with a single non-invasive PZ  
125 probe developed in a previous work [28], and shown in Figure 1(a) (main text). The  
126 probe is held in place by a neck collar specially developed for carotid measurements.  
127 The mechanical interface between the probe head and the sensing point also plays an  
128 important role on the data quality. The probe head is based on a mushroom-shaped PZ  
129 sensor that transmits the distension associated to the pressure wave in such a way that  
130 transversal and shear effects are suppressed and only radial applied forces are allowed.  
131 Accuracy tests were performed at a bench test, where 1.80% was the maximum Root






Figure 1: (a) Firstly, biochemical (CH-HDL - High density lipoprotein cholesterol and Total-CH - Cholesterol Total), pressure values (SBP - Systolic Blood Pressure and DBP - Diastolic Blood Pressure) and APW parameters (RWTT - Reflected Wave Transit Time, RWA - Reflection Wave Amplitude, SWTT - Systolic Wave Transit Time, LVET - Left Ventricular Ejection Time and AIx - Augmentation Index) were collected. (b) Four risk scores were studied to use as the reference along this work, namely: FRS - Framingham Risk Score, PROCAM - PROspective Cardiovascular Münster risk score, ASSIGN - ASsessing cardiovascular risk to Scottish Intercollegiate Guidelines Network and SCORE - Systematic COronary Risk Evaluation. (c) The Expectation Maximization (EM) and *k*-means were the selected clustering algorithms, and the Kruskal-Wallis Test was used to compare groups.

132 Mean Square Error (RMSE) introduced by the electronic circuits and by the mechanical  
133 interface.

134 Some data concerning validation was also published in [29] comprising three  
135 sets of recordings for the carotid pressure waveform at left and right carotid arteries,  
136 under standardized conditions, in 20 volunteers by three trained operators. Inter and  
137 intra-operator differences were calculated being good indicators, similar to other data  
138 reported in literature for commercial devices [30].

139 For each subject at least three consecutive measurements were performed. APW

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

140 parameters were tabulated for the set of pulses, considering each one of the subjects,  
141 after to the segmentation process. The PWA parameters, schematically represented in  
142 Figure 2, are related to amplitude and temporal characteristics of APW, namely:

- 143 • Reflected Wave Transit Time (RWTT) is determined by the time interval between  
144 the foot of the carotid pressure waveform to the first inflection point, which  
145 corresponds to the foot of the global reflected pressure wave.
- 146 • Reflection Wave Amplitude (RWA) is measured at inflection point in reference  
147 to the normalized amplitude.
- 148 • Systolic Wave Transit Time (SWTT) is defined as the interval between the  
149 waveform foot and the systolic peak.
- 150 • Left Ventricular Ejection Time (LVET) is measured by the time interval from the  
151 foot of the waveform to the dicrotic notch.
- 152 • Augmentation Index (AIx) is computed as the quotient between the reflected  
153 wave amplitude and the pulse pressure (PP), expressed as a percentage value.  
154 The equations used for its computation were defined by Murgo, *et. al.* (1980)  
155 [31], presented below. A type A waveform is defined when the systolic peak  
156 occurs in late systole after the inflection point and the type C when the systolic  
157 peak precedes the inflection point.

$$AIx = \pm \frac{SWA - RWA}{PP}$$

### 158 2.3. Risk Scores Selection

159 Four risk scores were considered along this work namely, FRS, PROCAM,  
160 ASSIGN and SCORE. The FRS was developed from a general population in  
161 Framingham, Massachusetts, USA, while the remaining scores derive from European




Figure 2: Arterial pressure waveforms measured non-invasively at carotid artery. In a) a type A contour is represented, where the peak systolic pressure (SP) occurs in late systole after an inflection point (Pi) that resulted from the reflection wave. In these conditions AIX is computed as a positive value. In b) a type C contour is represented. Notice that in a type C contour the SP precedes the Pi and AIX is computed as a negative value. The dicrotic wave is represented by DW.

162 studies. The largest is the SCORE, since it consists of  $\approx 205\,000$  subjects from 12  
 163 cohort studies from European countries. The other two, ASSIGN and PROCAM, were  
 164 developed in Scotland and Germany, respectively. In general, these tools have distinct  
 165 characteristics associated, different risk factors, specific disease, event type, period of  
 166 time and cohort locations. Table 1 summarizes the main characteristics for each one.

#### 167 2.4. Statistical Analysis

168 The data were analysed using the SPSS 16 statistical package (SPSS Inc.,  
 169 Chicago, Illinois, USA). Descriptive statistics were conducted to describe the sample  
 170 characteristics. The normality results were assessed by the Kolmogorov-Smirnov test.  
 171 To determine the relationships among variables, the Spearman rank-order correlation  
 172 test was used due to the non-normal nature of the distribution. Afterwards, also  
 173 due to the non-normal distribution the Kruskal-Wallis test was conducted to cluster  
 174 comparisons. A  $p$  value  $< 0.05$  was considered statistically significant.

Table 1: Risk assessment tools (10 years term).

Model	Patients	Country of Origin	Risk factors
FRS	8491	USA	Age, Gender, Total-CH, CH-HDL, SBP, BPT, SMK
SCORE	205178	Finland, Russia, Norway, Denmark, UK (England), UK (Scotland), Sweden, Belgium, Germany, Italy, France and Spain	Age, Gender, Total-CH, CH-HDL, SBP, and SMK
ASSIGN	13297	Scotland	Age, Gender, FH, DB, SMK, SBP, Total-CH and CH-HDL
PROCAM	5389	Germany	Age, CH-LDL, SMK, CH-HDL, SBP, PE, DB, and TGL

Total-CH – Total Cholesterol, BPT – Blood Pressure Treatment, FH – Family History, TGL – Triglycerides, SMK – Smoking habits, DB – Diabetes, PE – Previous Event, SBP – Systolic Blood Pressure, CH-HDL – High-Density Lipoprotein, CH-LDL – Low Density Lipoprotein.

## 175 2.5. Clustering Analysis

176 During the cluster assignments, the pulses are independently grouped according  
 177 to their cluster similarities. The adopted strategy for the determination of the ideal  
 178 number of clusters consisted, firstly, in the selection of two clusters ( $k = 2$ ) followed  
 179 by a tentative to split each of these clusters. During the process, clusters can also be  
 180 merged if they are sufficiently close or, if there is too many patterns and unusually large  
 181 variance.

182 The maximum level of similarity for each subject occurs when all pulses fit in only  
 183 one cluster. Expected Maximization (EM) and  $k$ -means clustering algorithms are the  
 184 most studied. Weka 3.6.8 framework software was the selected tool to use during the  
 185 cluster analysis (Figure 1(c)).

### 186 2.5.1. $k$ -Means

187 The  $k$ -means algorithm is a type of partitional clustering that continuously iterates  
 188 until a specific criterion function (usually the square error) converges. It acknowledges

1  
2  
3  
4  
5  
6  
7  
8  
9 189 the number of desired cluster inputs ( $k$ ) and divides the set of objects ( $n$ ) into  $k$  clusters.  
10 190 The result is a higher intra-cluster and lower inter-cluster similarity. The cluster  
11 191 similarity is measured considering the mean value of the objects contained in the  
12 192 cluster, which is, in fact, the cluster centroid.  $k$ -Means clustering is relatively scalable  
13 193 and efficient in processing large datasets. However, it cannot handle categorical  
14 194 attributes and it is not suitable for dealing with non-convex shapes. Also, it is quite  
15 195 sensitive to the presence of noise and outliers. It requires an efficient data pre-  
16 196 processing analysis before its application [23].

### 197 2.5.2. Expectation-Maximization

198 The Expectation-Maximization (EM) clustering algorithm is a complex  
199 probabilistic extension of the  $k$ -means method that primarily differs by the way how the  
200 initial groups are obtained. Instead of assigning each object to a cluster, with which it is  
201 most similar, EM assigns each object to a cluster according to a weight that represents  
202 the probability of membership. In this manner, there are no strict boundaries between  
203 clusters, and new means are determined based on weighted measures [23].

## 204 3. Results

### 205 3.1. Subject Characteristics

206 The clinical characteristics of our study population are shown in Table 2. The  
207 mean age of subjects in Group H is  $58.10 \pm 11.64$  years. The blood pressure values  
208 in this group are elevated ( $170.98 \pm 11.41$  mmHg and  $100.29 \pm 9.05$  mmHg for SBP  
209 and DBP, respectively) relatively to normal ranges, 130 – 139 mmHg for SBP and  
210 85 – 89 mmHg for DBP [3]. TGL is also a marker of increased risk in this group  
211 due to be higher than the guideline recommendations ( $< 150$  mg/dL) [3]. The same  
212 situation is verified for Total-CH values, which are also superior to the guideline  
213 recommendations ( $< 190$  mg/dL). However, the CH-HDL is within the optimal limits,  
214 as it is higher than the minimum threshold of 40 – 45 mg/dL. Finally, it is also possible

Table 2: Characteristics of subjects

Variable	Group H (mean±SD)	Group C (mean±SD)	Units
Number of subjects	23	93	–
Gender(m/f)	12/11	31/62	–
Age	58.10 ±11.64	21.19 ±2.28	years
SBP	170.98 ±11.41	108.26 ±11.88	mmHg
DBP	100.29 ±9.05	69.54 ±7.64	mmHg
BMI	27.87 ±5.23	21.62 ±2.63	kg/m <sup>2</sup>
Total-CH	205.10 ±25.42	–	mg/dL
CH-HDL	65.70 ±28.80	–	mg/dL
TGL	155.25 ±28.71	–	mg/dL
SWTT	224.08 ±52.86	163.45 ±60.64	ms
RWTT	115.83 ±27.93	159.29 ±43.47	ms
RWA	0.72 ±0.14	0.87 ±0.09	a.u. <sup>a</sup>
AIx	25.69 ±17.14	0.35 ±15.69	%
LVET	305.40 ±47.46	281.99 ±53.06	ms

SBP - Systolic Blood Pressure, DBP - Diastolic Blood Pressure, BMI - Body Mass Index, CH-HDL-High Density Lipoprotein Cholesterol, Total-CH - Cholesterol Total, TGL - Triglycerides, RWTT - Reflected Wave Transit Time, RWA-Reflection Wave Amplitude, SWTT - Systolic Wave Transit Time, LVET - Left Ventricular Ejection Time, AIx - Augmentation Index.

<sup>a</sup> Arbitrary amplitude units

215 to conclude that the mean Body Mass Index (BMI) in Group H is also superior to the  
216 ideal recommendations (< 25 kg/m<sup>2</sup>) [3].

217 Regarding Group C, the mean age is 21.19±2.28 years, and the pressure values  
218 are within normal ranges. Focusing on the APW differences between Group H and  
219 Group C, SWTT occurs later in the first group, where the arrival time assumes the value  
220 of 224.08 ± 52.86 ms, while in Group C, this is at 163.45 ± 60.64 ms. LVET arrival  
221 time is quite similar for both groups: 305.40 ± 47.46 ms in Group H and 281.99 ± 53.06  
222 ms in Group C. The RWTT occurs earlier in Group H (115.83 ± 27.93ms) at lower  
223 amplitude (0.72 ± 0.14), in opposition to the values in Group C (159.29 ± 43.47 ms,  
224 at the amplitude of 0.87 ± 0.09). Group H is also characterized by higher positive AIx  
225 values (25.69 ± 17.14 %), in opposition to the Group C (0.35 ± 15.69 %).

### 226 3.2. Clustering Analysis

227 The cluster analysis was performed for Group C and Group H, independently.  
228 Different nomenclatures were adopted to help understanding the data at hand, numeric  
229 labels (1, 2, ...) for the Group C and alphabet labels (A, B, ...) for the Group H. After,  
230 the cluster analysis, the clusters were compared using the Kruskal-Wallis test.

#### 231 3.2.1. Group C

232 The first approach consisted in the selection of the best clustering algorithm to deal  
233 with the set of features at test, as well as the ideal number of clusters to the group  
234 characterization. Figure 3 displays RWTT and SWTT plot for 2-clusters analysis using  
235 EM (a) and  $k$ -means (b) algorithms. Red and blue coloured points represent the pulse  
236 labels (blue = Cluster 1, red = Cluster 2). Categorical features (gender, smoker) were  
237 not considered during the analysis, since  $k$ -means analysis is not able to deal with this  
238 kind attributes.

239 The figure shows that the EM plot has an unsatisfactory division between the  
240 clusters, with some points from Cluster 2 identified as being in the Cluster 1 area.  
241 Visually, the results from the  $k$ -means clustering have a more efficient separation,  
242 as the dataset is partitioned in two homogeneous risk groups. For both EM and  
243  $k$ -means, the Cluster 1 represents the pool of healthier subjects when compared to  
244 the Cluster 2, since it represents the cases where the reflection wave arrives after to  
245 the systolic peak. The analysis of Cluster 2 also indicates the presence of another  
246 sub-cluster. Taking this into account, the  $k$ -means method was used to explore the  
247 distribution of a third cluster, since it performed well, comparatively to the EM, in the  
248 two cluster distribution. The obtained results for a 3 cluster distribution are presented in  
249 Figure 4. The detailed information about clusters distribution is presented in Table 3.  
250 The Cluster 3 (green homogeneous zone) is mostly representative of Type C APW  
251 pulses, where  $RWTT > SWTT$ . The mean AIX value of the cluster centroid is negative  
252 ( $-11.2\%$ ), thus being considered the lower risk cluster. Cluster 2 predominantly




Figure 3: Clusters performance obtained for EM (top) and *k*-means (bottom) algorithms using two clusters, Cluster 1=blue, Cluster 2=red.

253 consists of Type B pulses, with  $SWTT > RWTT$  and  $AIx > 0$ , being thus considered the  
 254 intermediate risk group. Cluster 1 pulses represents the less homogeneous group, with  
 255 some points also scattered across the Cluster 2 area. These pulses are mainly APW  
 256 Type A pulses, with some punctual Type B pulses. This group evidences a higher  
 257 cardiovascular risk comparatively to the Cluster 2 and Cluster 3.






Figure 4: RWTT and SWTT plot after  $k$ -means clustering for using three clusters. Blue=Cluster 1, red=Cluster 2 and Green=Cluster 3.

### 258 3.2.2. Group H

259 The  $k$ -means was also used in the Group H analysis. Figure 5 depicts the 2-cluster  
260 distribution, where Cluster A and Cluster B were the labels adopted.

Table 3: Average values for the 3-clusters groups.

Attributes	Cluster		
	1	2	3
Pulses	458	1550	2463
Age (y)	21.6	21.0	21.7
Weight (kg)	63.0	55.4	63.2
Height (m)	1.7	1.6	1.7
BMI (kg/m <sup>2</sup> )	21.3	20.8	21.8
SBP (mmHg)	109.9	106.1	108.6
DBP (mmHg)	69.6	70.3	68.9
HR (bpm)	72.8	67.5	72.9
SWTT (ms)	172.7	234.4	117.1
RWTT (ms)	103.0	143.2	179.9
LVET (ms)	240.3	306.4	274.4
SWA (a.u. <sup>a</sup> )	1.0	1.0	1.0
RWA (a.u. <sup>a</sup> )	0.8	0.9	0.9
DWA (a.u. <sup>a</sup> )	0.8	0.8	0.7
AIx (%)	21.0	12.6	-11.2

<sup>a</sup> Arbitrary Amplitude Units




Figure 5: Scatter plots for: (a) RWTT and RWA, (b) LVET and SWTT, where the grey and black markers denote Cluster A and Cluster B, respectively.

261 The characteristics of each of the clusters are presented in Table 4. It can be verified  
 262 that the clusters do not differ significantly according to the SBP and DBP values. The  
 263 most significant parameters (except APW parameters) were the CH-HDL and the TGL

Table 4: Cluster distributions for subjects in Group H.

Attributes	Cluster A	Cluster B
SBP (mmHg)	169.68±10.38	172.56±13.59
DBP (mmHg)	101.22±7.03	102.00±7.14
Total-CH (mg/dL)	206.50±26.16	204.01±13.69
CH-HDL (mg/dL)	59.35±25.07	66.33±23.31
TGL(mg/dL)	160.41±44.95	142.94±40.96
RWTT (ms)	99.90±23.62	140.32±42.76
RWA (a.u. <sup>a</sup> )	0.60±0.11	0.90±0.06
SWTT (ms)	257.34±35.76	185.34±40.70
LVET (ms)	326.24±39.43	272.16±44.17
AIx (%)	40.01±11.15	6.2±9.67
Clustered instances	723 (52 %)	664 (48 %)

<sup>a</sup> Arbitrary Amplitude Units

1  
2  
3  
4  
5  
6  
7  
8  
9 264 values. Cluster A is characterized by higher TGL values and lower CH-HDL levels,  
10 265 characteristics of subjects at risk. From the waveform analysis, lower RWTT, higher  
11 266 SWTT and, consequently, higher positive AIx values were obtained. The suitable  
12 267 number of clusters was considered to be two as may be confirmed by visual inspection.

13  
14  
15 268 During the evaluation, the pulse instances were independently grouped according  
16 269 to their cluster similarities, being the maximum level of similarity achieved, for each  
17 270 subject, when all the pulses fit in a single cluster. So, for each subject a value  
18 271 representing the cluster risk (as percentage) was computed and used in the correlation  
19 272 with other available parameters (including the studied scores). Since only two clusters  
20 273 are studied, at this point, the values of Cluster A (%) are symmetric to the values of  
21 274 Cluster B (%). The Cluster A (%) correlations are presented in Table 5.

22  
23  
24  
25  
26  
27 275 The lipidic and the BP values present low significance with the Cluster A (%). On  
28 276 the other hand, significant correlation values were obtained between Cluster A (%)

29  
30  
31  
32  
33 Table 5: Spearman's correlation coefficients  
34 obtained for Cluster A (%).

Attributes	Cluster A (%)
SBP	-0.131
DBP	-0.080
Total-CH	0.011
CH-HDL	-0.177
TGL	0.017
AIx	0.921 **
SWTT	0.649 **
RWTT	-0.632 **
RWA	-0.933 **
LVET	0.574 **
FRS	0.458 *
SCORE	0.275
ASSIGN	0.582 **
PROCAM	0.391

35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56 Significant levels: \*\*  $p < 0.01$ , \*  $p < 0.05$

277 and PWA parameters. Additionally, it was obtained a significant correlation between  
 278 Cluster A (%) and the risk scores. In this case was observed a very significant  
 279 correlation with ASSIGN ( $r = 0.582$ ,  $p < 0.01$ ), a significant correlation with FRS  
 280 ( $r = 0.458$ ,  $p < 0.05$ ) and, weaker correlations with SCORE ( $r = 0.275$ ,  $p = 0.241$ )  
 281 and PROCAM ( $r = 0.391$ ,  $p = 0.088$ ). These results are good indicators for the use of  
 282 this methodology as a tool for the cardiovascular risk assessment.

283 Figure 6 shows the cluster A (%) distribution (considering a threshold of more than  
 284 50 %) for each of the scores. Targeting data by cluster A (threshold  $>50\%$ ), obtained  
 285 a median risk by the SCORE function of 2.0% per year, FRS function of 13.0% per  
 286 year, ASSIGN function of 16.0% per year and by the PROCAM function of 20.7%  
 287 per year. For the FRS, ASSIGN and PROCAM scores, these values correspond to the  
 288 borderline between high risk and an intermediate risk [32, 33]. However, for SCORE,  
 289 the observed median value corresponds to low risk, being SCORE the less correlated




Figure 6: Boxplots of CHD risk distribution for SCORE, FRES, ASSIGN and PROCAM. The horizontal lines represent the medians, the boxes represent the interquartile ranges (50% of the distribution) and the whiskers represent the range of values obtained for subjects from GroupH.

function with the cluster results.

### 3.2.3. Comparison of Groups

The evaluation was performed by the comparison of the clusters in Group H (Cluster A and Cluster B) with clusters in Group C (Cluster 1, Cluster 2 and Cluster 3). The Cluster A is the cluster at higher risk in the hypertensive groups, as previously discussed. Since, there is no medical information about the risk associated to Group C (we have only informations concerning the APW parametrizations), each one of clusters from Group C was compared to the Group H clusters. The comparison was performed using the chi-squared ( $\chi^2$ ) value, obtained from the Kruskal-Wallis test, as shown in Table 6.

There are significant differences for the majority of clusters in Group H and Group C, as expected due to the distinct population characteristics of each group. However, some similarities were found between the Cluster B (the score at lower risk in Group H) and the Cluster 1 (belonging to the Group C), namely: for LVET ( $\chi^2 = 4.79$ ,  $p < 0.01$ ) and SWTT ( $\chi^2 = 0.02$ ,  $p < 0.01$ ) measures. From the analysis of Table 3, it is possible to conclude that this is the cluster at higher risk in Group C. However, it is not possible to conclude that the risk associated is effectively risk

Table 6: Comparison of clusters from Group H (Cluster A and Cluster B) and Group C (Cluster 1, Cluster 2 and Cluster 3) using Kruskal-Wallis test, measured through  $\chi^2$  value.

Group H	Group C	Parameters					
		RWTT	RWA	SWTT	RWTT	LVET	AIx
ClusterA	Cluster1	38.66 **	402.42**	526.65**	38.66**	369.23**	402.40 **
	Cluster2	1149.82**	1399.96 **	248.87 **	1149.82**	154.81 **	1399.97**
	Cluster3	1454.05**	1545.50**	1619.16**	1454.05**	706.65**	1638.37**
ClusterB	Cluster1	536.38 **	458.25**	0.02	536.38**	4.79	538.34 **
	Cluster2	265.77**	3.16 **	892.34 **	265.77**	598.03**	49.97 **
	Cluster3	593.88**	4.06**	998.62**	593.88**	60.22**	1158.33**

Significant levels: \*\*  $p < 0.01$

1  
2  
3  
4  
5  
6  
7  
8  
9 307 associated to the development of CVD. This conclusion is only possible from the  
10 308 comparison with the clusters of the hypertensive group (Group H). And, the similarities  
11 309 are evident for the cluster in analysis (Cluster 1) and the cluster at lower risk in the  
12 310 hypertensive group (Cluster B), leading to assume that the subjects belonging to the  
13 311 Cluster 1 need medical advice, and that they may be developing CVD. It would not be  
14 312 trustable, if the similarities occur for the group of subjects in advanced stage of disease  
15 313 (Cluster A). This conclusion supports that is possible to screen a healthy population  
16 314 (using only waveform parameters) concerning the cardiovascular risk using clustering  
17 315 methodologies.

#### 316 4. Discussion

317 In this paper a new approach to morphological pulse analysis is presented, and  
318 an innovative methodology to cardiovascular risk assessment, taking as reference the  
319 CHD risk scores, is applied.

320 The information that is extracted from the clustering analysis can be crucial to fully  
321 understand of the data, mainly when there is no, or little, available information. It was  
322 verified, that Total-CH and TGL values are intrinsically related to the APW variables,  
323 and than an increase of these levels is associated to the RWTT decrease and SWTT  
324 increase. On the other hand, the higher CH-HDL values are associated to the increase  
325 of RWTT and decrease of SWTT values. Significant correlations for the cluster output  
326 with the ASSIGN ( $r = 0.582$ ,  $p < 0.01$ ) and with FRS ( $r = 0.458$ ,  $p < 0.05$ ) were also  
327 verified.

328 This method is particularly interesting, considering that this approach can avoid the  
329 requirements of the classification procedures which often require costly labelling of a  
330 large set of patterns, such as biochemical analysis used by traditional risk scores, as  
331 demonstrated on the cluster analysis of subjects in Group C. It was possible to identify  
332 the similarities with Group H clusters, using only morphological parameters. The

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

333 possibility to emulate the performance of the traditional risk scores by the use of only  
334 non-invasive parameters, which can be easily obtained using a PWA technique, is an  
335 efficient alternative approach to study large datasets. In this sense, clustering analysis  
336 is an easy method for large populations screening producing valuable knowledge for  
337 posterior prioritising people for pharmacological measures.

338 The healthcare public and private system faces the challenge of an increasingly  
339 aging population and the escalation of medical costs. Therefore, the development of  
340 techniques that allow for earlier identification of subjects at risk, by the incorporation  
341 of personalized, predictive and preventive methodologies, could bring an interesting  
342 impact comparatively to the traditional cardiovascular tools used for risk prediction.  
343 It is evident the foreseeable impact that an accurate, non-invasive and easy-to-use  
344 instrument for hemodynamic condition assessment could impart on the diagnosis and  
345 follow-up of the CVD. However, a similar methodology could be applied to other  
346 measurements (*e. g.*, invasive pressures, electrocardiogram) used in traditional clinical  
347 path of cardiovascular patients.

## 348 **5. Conclusions**

349 This paper demonstrates the utility of clustering techniques in risk scoring when  
350 applied to a medical dataset. When compared with the traditional risk scores, clustering  
351 methodologies showed good performance with significant correlation values. This is a  
352 simple, yet reliable tool, that can be used in scoring trials.

353 As this approach needs some developments, a computational tool to integrate these  
354 results with other machine learning techniques such as classification algorithms, is  
355 currently being developed [15]. A larger sample will also be studied in future trials  
356 for the stratification by medication use, age, diabetes duration, and/or gender. Given  
357 these considerations, this application can be an interesting methodology to be used  
358 in further clinical studies to pulse morphological analysis. It can also be potentially

1  
2  
3  
4  
5  
6  
7  
8  
9 359 useful in other medical applications, such as in the anaesthesiology room, where the  
10 360 number of parameters and devices are high, as a tool that incorporates several important  
11  
12 361 information.  
13  
14

## 15 362 **Acknowledgements**

16  
17  
18 363 Authors acknowledge *Fundação para a Ciência e Tecnologia* for funding  
19 364 scholarship SFRH/BD/61356/2009 and PTDC/SAU-BEB/100650/2008, project  
20  
21 365 developed under the initiative of QREN, funding by UE/FEDER, through *COMPETE-*  
22  
23 366 *Programa Operacional Factores de Competitividade*. The authors also thanks to ISA-  
24  
25 367 Intelligent Sensing Anywhere and Hospital and University Coimbra Center (*C.H.U.C.*)  
26  
27 368 for the collaboration in clinical trials.  
28  
29

## 30 369 **References**

- 31  
32  
33 370 [1] W. H. Organization, The global burden of disease: 2004 update, World Health  
34 371 Organization.  
35  
36  
37 372 [2] R. E. W. Kavey, S. R. Daniels, R. M. Lauer, D. L. A. Atkins, L. L. Hayman,  
38 373 K. Taubert, American heart association guidelines for primary prevention  
39 374 of atherosclerotic cardiovascular disease beginning in childhood, *Circulation*  
40  
41 375 107 (11) (2003) 1562–1566.  
42  
43  
44  
45 376 [3] J. Perk, G. De Backer, H. Gohlke, I. Graham, Z. Reiner, M. Verschuren,  
46 377 C. Albus, P. Benlian, G. Boysen, R. Cifkova, C. Deaton, S. Ebrahim, M. Fisher,  
47 378 G. Germano, R. Hobbs, A. Hoes, S. Karadeniz, A. Mezzani, E. Prescott,  
48 379 L. Ryden, M. Scherer, M. Syvanne, W. J. Scholte op Reimer, C. Vrints, D. Wood,  
49  
50 380 J. L. Zamorano, F. Zannad, European guidelines on cardiovascular disease  
51  
52 381 prevention in clinical practice (version 2012). The fifth joint task force of the  
53  
54 382 european society of cardiology and other societies on cardiovascular disease  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4  
5  
6  
7  
8  
9 383 prevention in clinical practice (constituted by representatives of nine societies  
10 384 and by invited experts). developed with the special contribution of the european  
11 385 association for cardiovascular prevention & rehabilitation (eacpr), Eur Heart J  
12 386 33 (13) (2012) 1635–701.

13  
14  
15  
16  
17 387 [4] A. Beswick, P. Brindle, Risk scoring in the assessment of cardiovascular risk,  
18 388 Curr Opin Lipidol 17 (2006) 375–386.

19  
20  
21 389 [5] M. D. Whitfield, M. Gillett, M. Holmes, E. Ogden, Predicting the impact of  
22 390 population level risk reduction in cardio-vascular disease and stroke on acute  
23 391 hospital admission rates over a 5 year period—a pilot study, Public Health 120 (12)  
24 392 (2006) 1140–8.

25  
26  
27  
28  
29 393 [6] M. T. Cooney, A. L. Dudina, I. M. Graham, Value and limitations of existing  
30 394 scores for the assessment of cardiovascular risk: a review for clinicians, J Am  
31 395 Coll Cardiol 54 (14) (2009) 1209–27.

32  
33  
34 396 [7] G. C. M. Siontis, I. Tzoulaki, K. C. Siontis, J. P. A. Ioannidis, Comparisons of  
35 397 established risk prediction models for cardiovascular disease: systematic review,  
36 398 BMJ 344. doi:10.1136/bmj.e3318.

37  
38  
39  
40 399 [8] I. U. Haq, L. E. Ramsay, W. Yeo, P. R. Jackson, E. J. Wallis, Is the framingham  
41 400 risk function valid for northern european populations? a comparison of methods  
42 401 for estimating absolute coronary risk in high risk men, Heart Vessels 81 (1999)  
43 402 40–46.

44  
45  
46  
47  
48 403 [9] G. M. London, A. P. Guerin, Influence of arterial pulse and reflected waves on  
49 404 blood pressure and cardiac function, Am Heart J 138 (3) (1999) 220–223.

50  
51  
52 405 [10] J. D. Cameron, B. P. McGrath, A. M. Dart, Use of radial artery applanation  
53 406 tonometry and a generalized transfer function to determine aortic pressure  
54  
55  
56  
57  
58

- 1  
2  
3  
4  
5  
6  
7  
8  
9 407 augmentation in subjects with treated hypertension, *JACC* 32 (5) (1998) 1214–  
10 408 20.
- 11  
12  
13 409 [11] S. Laurent, J. Cockcroft, L. V. Bortel, P. Boutouyrie, C. Giannattasio, D. Hayoz,  
14 410 B. Pannier, C. Vlachopoulos, I. Wilkinson, H. Struijker-Boudier, Expert consensus  
15 411 document on arterial stiffness methodological issues and clinical applications,  
16 412 *European Heart Journal* 27 (21) (2006) 2588–2605.
- 17  
18  
19  
20  
21 413 [12] I. Ikonomidis, S. Tzortzis, T. Papaioannou, A. Protogerou, K. Stamatelopoulos,  
22 414 C. Papamichael, N. Zakopoulos, J. Lekakis, Incremental value of arterial wave  
23 415 reflections in the determination of left ventricular diastolic dysfunction in  
24 416 untreated patients with essential hypertension, *J Hum Hypertens* 22 (10) (2008)  
25 417 687–98.
- 26  
27  
28  
29  
30 418 [13] A. P. Avolio, M. Butlin, A. Walsh, Arterial blood pressure measurement and pulse  
31 419 wave analysis—their role in enhancing cardiovascular assessment, *Physiol Meas*  
32 420 31 (1) (2010) R1–47.
- 33  
34  
35  
36 421 [14] B. Hametner, S. Wassertheurer, J. Kropf, C. Mayer, A. Holzinger, B. Eber,  
37 422 T. Weber, Wave reflection quantification based on pressure waveforms  
38 423 alone—methods, comparison, and clinical covariates, *Computer Methods and*  
39 424 *Programs in Biomedicine* 109 (3) (2013) 250 – 259.
- 40  
41  
42  
43  
44 425 [15] V. Almeida, J. Vieira, P. Santos, T. Pereira, H. Pereira, C. Correia, M. Pego,  
45 426 J. Cardoso, Machine learning techniques for arterial pressure waveform analysis,  
46 427 *Journal of Personalized Medicine* 3 (2) (2013) 82–101.
- 47  
48  
49  
50 428 [16] I. Yoo, P. Alafaireet, M. Marinov, K. PenaHernandez, R. Gopidi, J. Chang,  
51 429 L. Hua, Data mining in healthcare and biomedicine: A survey of the literature, *J.*  
52 430 *Med. Syst.*
- 53  
54  
55  
56 431 [17] K. B. Waghlikar, V. Sundararajan, A. W. Deshpande, Modeling paradigms for  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10 432 medical diagnostic decision support: a survey and future directions, *J Med Syst*  
11 433 36 (5) (2012) 3029–49.
- 12  
13 434 [18] M. G. Tsipouras, T. P. Exarchos, D. I. Fotiadis, A. Kotsia, K. Vakalis, K. K.  
14 435 Naka, L. K. Michalis, Automated diagnosis of coronary artery disease based on  
15 436 data mining and fuzzy modeling, *IEEE Transactions On Information Technology*  
16 437 *In Biomedicine* 12 (4) (2008) 447–458.
- 17  
18  
19  
20  
21 438 [19] S. Paredes, T. Rocha, P. de Carvalho, J. Henriques, M. Harris, J. Morais,  
22 439 Long term cardiovascular risk models' combination, *Comput Methods Programs*  
23 440 *Biomed* 101 (3) (2011) 231–42.
- 24  
25  
26  
27 441 [20] A. Jovic, N. Bogunovic, Electrocardiogram analysis using a combination of  
28 442 statistical, geometric, and nonlinear heart rate variability features, *Artificial*  
29 443 *Intelligence in Medicine* 51 (2011) 175–186.
- 30  
31  
32  
33 444 [21] L. I. Kuncheva, J. C. Bezdek, R. P. Duin, Decision templates for multiple classifier  
34 445 fusion: An experimental comparison, *Pattern Recognition Letters* 34 (2).
- 35  
36  
37 446 [22] D. Ruta, B. Gabrys, An overview of classifier fusion methods, *Computing and*  
38 447 *Information Systems* 7.
- 39  
40  
41 448 [23] J.Han, M. Kamber, *Data mining. Concepts and techniques*, Elsevier, San  
42 449 *Francisco, CA, 2006.*
- 43  
44  
45 450 [24] V. Melnykov, G. Shen, *Clustering through empirical likelihood ratio,*  
46 451 *Computational Statistics Data Analysis.*
- 47  
48  
49  
50 452 [25] A. S. Shah, L. M. Dolan, Z. Gao, T. R. Kimball, E. M. Urbina, Clustering of risk  
51 453 factors: a simple method of detecting cardiovascular disease in youth, *Pediatrics*  
52 454 127 (2) (2011) e312–8.
- 53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- 455 [26] H. H. Haseena, A. T. Mathew, J. K. Paul, Fuzzy clustered probabilistic and  
456 multi layered feed forward neural networks for electrocardiogram arrhythmia  
457 classification, *J Med Syst* 35 (2) (2011) 179–88.
- 458 [27] J. Namayanja, V. P. Janeja, An assessment of patient behavior over time–periods:  
459 A case study of managing type 2 diabetes through blood glucose readings and  
460 insulin doses, *Journal of Medical Systems* 36 (S1) (2012) 65–80.
- 461 [28] V. G. Almeida, H. C. Pereira, T. Pereira, E. Figueiras, E. Borges, J. M. R. Cardoso,  
462 C. Correia, Piezoelectric probe for pressure waveform estimation in flexible tubes  
463 and its applications to the cardiovascular system, *Sensors and Actuators A* 169  
464 (2011) 217–226.
- 465 [29] V. Almeida, H. Pereira, T. Pereira, L. Ferreira, C. Correia, J. Cardoso, Assessment  
466 of the pulse wave variability for a new non-invasive device, in: Y.-T. Zhang  
467 (Ed.), *The International Conference on Health Informatics*, Vol. 42 of IFMBE  
468 *Proceedings*, Springer International Publishing, 2014, pp. 240–243.
- 469 [30] M. Frimodt-Moller, A. H. Nielsen, A. L. Kamper, S. Strandgaard, Reproducibility  
470 of pulse-wave analysis and pulse-wave velocity determination in chronic kidney  
471 disease, *Nephrol Dial Transplant* 23 (2) (2008) 594–600.
- 472 [31] J. Murgo, N. Westerhof, J. P. Giolma, S. Altobelli, Aortic input impedance in  
473 normal man: relationship to pressure wave forms, *circulation*, *Circulation* 62  
474 (1980) 105–116.
- 475 [32] M. Versteyleen, I. Joosen, L. Shaw, J. Narula, L. Hofstra, Comparison  
476 of framingham, procam, score, and diamond forrester to predict coronary  
477 atherosclerosis and cardiovascular events, *Journal of Nuclear Cardiology* 18 (5)  
478 (2011) 904–911.
- 479 [33] Assign score website, <http://assign-score.com/> (2014).